Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Capital Expenditures (2016 - 2025)

Altimmune (ALT) has disclosed Capital Expenditures for 14 consecutive years, with $1000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed N/A to $1000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $11000.0 for FY2025, N/A changed from the prior year.
  • Capital Expenditures for Q4 2025 was $1000.0 at Altimmune, up from -$4000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $7.7 million in Q2 2021, with the low at -$4000.0 in Q2 2023.
  • Average Capital Expenditures over 4 years is $1.1 million, with a median of $51000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures skyrocketed 34127.86% in 2021, then crashed 121.05% in 2023.
  • Over 4 years, Capital Expenditures stood at $147000.0 in 2021, then crashed by 74.15% to $38000.0 in 2022, then tumbled by 110.53% to -$4000.0 in 2023, then skyrocketed by 125.0% to $1000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $1000.0, -$4000.0, and $51000.0 for Q4 2025, Q2 2023, and Q1 2023 respectively.